As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Radiopharm Theranostics Limited. The largest reported stake is Lantheus Omega, LLC's, at 17.3%. 7 filings are on record since July 16, 2025 (Schedule 13G, September 4, 2026).
Sell to companies like Radiopharm Theranostics Limited? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Regal Partners Funds Management Pty Limited · Sole voting: 0 · Shared voting: 157,139,443 · Sole dispositive: 0 · Shared dispositive: 157,139,443 · SCHEDULE 13G, 2026-10-14
- · Reporting person: Lantheus Omega, LLC · Sole voting: 0 · Shared voting: 792,958,513 · Sole dispositive: 0 · Shared dispositive: 792,958,513 · SCHEDULE 13G, 2026-09-04
- · Holder: Lantheus Holdings, Inc. · Percent: 20.9% · SCHEDULE 13D
- · Reporting person: Jpmorgan Chase & Co. · Sole voting: 145,679,951 · Shared voting: 0 · Sole dispositive: 145,679,951 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-01-16
- · Holder: Regal Partners Holdings Pty Limited · Percent: 9.05% · SCHEDULE 13G
Radiopharm Theranostics Limited has 7 Schedule 13D or 13G filings on record since 2025-07-16. 2 holders' latest filing reports 5% or more of ordinary shares, no par value and american depositary shares, each representing three hundred ordinary shares, no par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Lantheus Omega, LLC | 17.3% | 792,958,513 | SCHEDULE 13G, 2026-09-04 | 2026-07-28 |
| Regal Partners Holdings Pty Limited | 9.05% | 320,694,680 | SCHEDULE 13G, 2026-01-08 | 2025-12-31 |
| Jpmorgan Chase & Co. | 4% | 145,679,951 | SCHEDULE 13G/A, 2026-01-16 | 2025-12-31 |
| Regal Partners Funds Management Pty Limited | 3.34% | 157,139,443 | SCHEDULE 13G, 2026-10-14 | 2026-09-30 |
Holding shares or following this stake? See who's behind Radiopharm Theranostics Limited and the warning signs.
Free to see. No signup.
Keep reading
More on Radiopharm Theranostics Limited and the records around it.
Radiopharm Theranostics Limited elsewhere on the record
Companies that share a holder
- Lantheus Omega, LLC also filed stake reports on 1 other company: Perspective Therapeutics, Inc. (Sep 2026)
- Regal Partners Funds Management Pty Limited also filed stake reports on 1 other company: EBR Systems, Inc. (Jul 2026)
- JPMORGAN CHASE & CO. also filed stake reports on 116 other companies: LEVI STRAUSS & CO (Nov 2026), Warner Music Group Corp. (Nov 2026), Andersen Group Inc. (Oct 2026)
Watch Radiopharm Theranostics Limited
Get an email when Radiopharm Theranostics Limited files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Radiopharm Theranostics Limited?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Radiopharm Theranostics Limited: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Radiopharm Theranostics Limited covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Lantheus Omega, LLC | 0 | 792,958,513 | 0 | 792,958,513 | SCHEDULE 13G, 2026-09-04 |
| Lantheus Medical Imaging, Inc. | 0 | 792,958,513 | 0 | 792,958,513 | SCHEDULE 13G, 2026-09-04 |
| Lantheus Holdings, Inc. | 0 | 792,958,513 | 0 | 792,958,513 | SCHEDULE 13G, 2026-09-04 |
| Jpmorgan Chase & Co. | 145,679,951 | 0 | 145,679,951 | 0 | SCHEDULE 13G/A, 2026-01-16 |
| Regal Partners Funds Management Pty Limited | 0 | 157,139,443 | 0 | 157,139,443 | SCHEDULE 13G, 2026-10-14 |
| Regal Partners Limited | 0 | 157,139,443 | 0 | 157,139,443 | SCHEDULE 13G, 2026-10-14 |
The latest filing identifies Radiopharm Theranostics Limited by CUSIP 75041J101 and gives its principal executive office as Level 3, 62 Lygon Street, Carlton Vic (SCHEDULE 13G, 2026-10-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-16 | Jpmorgan Chase & Co. | 9% | SCHEDULE 13G/A |
| 2025-07-23 | Regal Funds Management Pty Limited | 7.3% | SCHEDULE 13G |
| 2026-01-08 | Regal Partners Holdings Pty Limited | 9.05% | SCHEDULE 13G |
| 2026-01-16 | Jpmorgan Chase & Co. | 4% | SCHEDULE 13G/A |
| 2026-09-04 | Lantheus Holdings, Inc. | 20.9% | SCHEDULE 13D |
| 2026-09-04 | Lantheus Omega, LLC | 17.3% | SCHEDULE 13G |
| 2026-10-14 | Regal Partners Funds Management Pty Limited | 3.34% | SCHEDULE 13G |
Questions about who owns Radiopharm Theranostics Limited
Who owns Radiopharm Theranostics Limited?
On this page, 2 holders' latest ownership filings report 5% or more of Radiopharm Theranostics Limited: Lantheus Omega, LLC (17.3%, Schedule 13G, filed 2026-09-04) and Regal Partners Holdings Pty Limited (9.05%, Schedule 13G, filed 2026-01-08).
Who are the largest shareholders of Radiopharm Theranostics Limited?
By the share each holder's latest filing reports, the largest holders of Radiopharm Theranostics Limited on this page are Lantheus Omega, LLC (17.3%) and Regal Partners Holdings Pty Limited (9.05%).
When did Lantheus Omega, LLC buy into Radiopharm Theranostics Limited?
The filings give report dates, not purchase dates. The earliest filing from Lantheus Omega, LLC on this page is the Schedule 13G, filed 2026-09-04, reporting 17.3%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Radiopharm Theranostics Limited. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.